Topotecan-induced celluitis-like fixed drug eruption.
Senturk
N
N
Yanik
F
F
Yildiz
L
L
Aydin
F
F
Canturk
T
T
Turanli
A Y
AY
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001707:Biopsy, Needle; D002481:Cellulitis / Q000139:chemically induced* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007262:Infusions, Intravenous; D007868:Leg Dermatoses / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy / Q000379:methods; D018570:Risk Assessment; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects*
D019772:Topotecan